No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe the changes in serum levels of calcitonin in liraglutide- and placebo-treated patients in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial over a 3.5–5-year period. RESEARCH DESIGN AND METHODS: Patients (n = 9,340) with type 2 diabetes and high risk for cardiovascular events were randomized 1:1 to liraglutide or placebo. We analyzed calcitonin levels, thyroid and C-cell adverse events, and neoplasms. RESULTS: At 36 months, patients randomized to liraglutide versus placebo showed no evidence of increase in calcitonin concentrations in male (estimated treatment ratio [ETR] 1.03 [95% CI 1.00, 1.06]; P = 0.068) and female (ETR 1.00 [95% CI 0.97, 1.02]; P = 0.671) subgroups. There were no episodes of C-cell hyperplasia or medullary thyroid carcinoma in liraglutide-treated patients. CONCLUSIONS: There was no evidence of a difference in calcitonin concentrations between the liraglutide and placebo groups, and no C-cell malignancies occurred in the liraglutide group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1793]
In the citing paper
“In the LEADER trial, at 36 months, there was no difference in the levels of calcitonin between participants in the placebo or liraglutide arm and no diagnoses of C-cell hyperplasia or MTC in those who received liraglutide and there was one event of MTC in the placebo arm.57”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [57]
In the citing paper
“there was no difference between liraglutide and placebo regarding calcitonin levels and C-cell malignancies”
From Safety of Semaglutide (2021) · cites this paper as [83]
In the citing paper
“A phase 3b RCT showed no difference in the calcitonin levels and rate of medullary thyroid carcinoma between the placebo- and liraglutide-treated (≤ 1.8 mg) groups, during a follow-up after 3.5 years [55].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [55]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 245
Self-citationHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 3×
“In contrast, a different study showed that the calcitonin concentrations were statistically higher at weeks 26 and 52 with liraglutide compared with comparators; however, these levels were well within the normal range and, as with our analysis, showed no indication that these differences were of clinical significance…”
BackgroundResultInfluentialSelf-citationMadsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161
Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls
Costante, G., Durante, C., Francis, Z., Schlumberger, M. J., & Filetti, S. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1023 · Cited by 143 · cited 5×
“In rodent studies, but not in nonhuman primate and clinical studies, glucagon-like peptide 1 receptor activation has been associated with CCH, C-cell adenomas, and C-cell carcinomas (6–8).”
BackgroundMethodInfluentialRoutine serum calcitonin measurement in the evaluation of thyroid nodules
Elisei, R. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.008 · Cited by 98 · cited 1×
“The role of routine calcitonin monitoring for detection of MTC remains ill-defined but may be a more sensitivemethod in establishingMTC than cytology in patients with thyroid nodules (5).”
BackgroundMachens, A., Hoffmann, F., Sekulla, C., & Dralle, H. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0136 · Cited by 83 · cited 1×
“The progression of CCH to MTC is accompanied by rising calcitonin concentrations (2,3).”
BackgroundMedical management of metastatic medullary thyroid cancer
Maxwell, J. E., Sherman, S. K., O’Dorisio, T. M., & Howe, J. R. (2014) · Cancer · doi:10.1002/cncr.28858 · Cited by 49
Self-citationDaniels, G. H., Hegedüs, L., Marso, S. P., Nauck, M. A., Zinman, B., Bergenstal, R. M., Mann, J. F. E., Derving Karsbøl, J., Moses, A. C., Buse, J. B., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12444 · Cited by 42
Self-citation
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Metadata
- Authors
- Hegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators
- Affiliations
- Department of Endocrinology, Odense University Hospital, Odense, Denmark
- The University of Texas MD Anderson Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Harvard University (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-26
- Volume
- 41
- Issue
- 3
- Pages
- 620-622
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2778933123
- Cited by
- 67
- References
- 10
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 12 · 2023: 10 · 2022: 6 · 2021: 2 · 2020: 9 · 2019: 6 · 2018: 3
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- liraglutide, calcitonin, C-cell hyperplasia, medullary thyroid carcinoma, type 2 diabetes, GLP-1 receptor agonists, thyroid cancer risk, long-term safety, cardiovascular outcomes, LEADER trial
- MeSH terms
- Liraglutide, Calcitonin, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperplasia, Hypoglycemic Agents, Male, Middle Aged, Neoplasms, Thyroid Neoplasms, Biomarkers, Tumor, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.